We focused on P4/E2 treatment because there is a functional crosstalk between PR and ERα [16], and P4/E2 treatment better recapitulates physiological hormonal scenarios in T-47D cells than P4 alone since breast cancer cells in patients are also exposed simultaneously to both hormones. The gene discussed is PGR; the disease is breast cancer.